At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 376 enrolled
Drug / intervention
0.15% Brimonidine Tartratedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension
In Brief
A Phase 4 clinical trial evaluating 0.15% Brimonidine Tartrate for Glaucoma, Open-Angle and Ocular Hypertension. Completed, enrolled 376 participants across 1 site.
Detailed Summary
This study will evaluate 0.15% brimonidine tartrate in patients with primary open angle glaucoma and ocular hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Open-Angle, Ocular Hypertension
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2010
Primary CompletionFeb 2013
First PostedDec 2013
TodayJul 2026
First PostedDec 6, 2013
Enrollment StartJul 1, 2010
Primary CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 12.6 years ago
Interventions
0.15% Brimonidine Tartratedrug
0.15% Brimonidine Tartrate (Alphagan® P) 1 drop in the affected eye 3 times daily for 3 months.